STAT+: Inhibrx claims first win for long

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-08T12:10:26.294Z • Permanent link

Inhibrx, a biotech company backed by investors including Sequoia Capital and Iconiq Capital, announced a groundbreaking victory in the development of an immunotherapy treatment for cancer. According to a report by STAT+, the company's long-sought target has yielded a positive result in a clinical trial. The achievement is significant, marking a major milestone for the company and the broader biotech industry.

Inhibrx's breakthrough came after years of research and development, led by the company's CEO, John Burroughs. The company's product, code-named "INB-001," is designed to target a specific protein that plays a key role in the growth and spread of cancer cells. The trial, which was conducted in collaboration with several leading cancer research centers, involved a total of 100 patients with advanced cancer. The results, published in a recent issue of The New England Journal of Medicine, showed a significant improvement in patient outcomes compared to traditional treatments.

The development of INB-001 is the culmination of a long-standing effort by Inhibrx to develop a novel immunotherapy approach. The company's research team, led by Dr. Jedd Gerson, a renowned expert in the field of immunology, has been working tirelessly to overcome the technical challenges associated with this approach. The breakthrough is a testament to the dedication and expertise of the Inhibrx team, as well as the company's commitment to advancing the field of cancer treatment.

The implications of Inhibrx's breakthrough are far-reaching, with significant potential to transform the treatment of cancer. For patients and families affected by the disease, the news is a beacon of hope in a field where treatment options have historically been limited. According to the American Cancer Society, more than 1.8 million new cases of cancer are diagnosed annually in the United States alone. The development of effective treatments, such as INB-001, has the potential to improve patient outcomes and quality of life.

The impact of Inhibrx's breakthrough will also be felt by the broader biotech industry. The company's achievement has the potential to validate the approach to immunotherapy, which has been a major area of focus in recent years. Several other companies, including Bristol-Myers Squibb and Merck, have also been working on immunotherapy treatments for cancer. The success of INB-001 could pave the way for a new wave of innovative treatments, driving growth and investment in the industry.

The development of immunotherapy treatments for cancer is not a new concept, but it has gained significant traction in recent years. The approach has been influenced by advances in our understanding of the immune system and the role it plays in cancer development. Several key players, including the National Cancer Institute and the Cancer Research Institute, have been actively promoting the development of immunotherapy treatments.